Forest Laboratories, Inc.

  • The Next Big Opportunity in Antidepressant Drugs

    By Kanak Kanti - August 14, 2013 | Tickers: LLY, FRX, PFE

    The economic cost to the country of 16 million depressed Americans is $44 billion every year. Depression, concomitant with a sedentary lifestyle, is becoming a global phenomenon. It is the leading cause of disability among all medical illnesses. Technically known as Major Depressive Disorder (MDD), depression has a number of medications that are neither very effective nor very safe. Fetzima, a newly FDA-approved drug from Forest Laboratories (NYSE: FRX), promises more »

  • Marketed Drugs, Strong Pipeline, Long Term Growth Stock

    By Kanak Kanti - July 30, 2013 | Tickers: CBST, FRX, OPTR

    In June this year, a drug candidate from Cubist Pharmaceuticals (NASDAQ: CBST) received fast track status from the FDA. This product can potentially help around 2 million American patients who suffer from Gram negative bacteria infection every year. Just a small chunk of this market – gram negative bacteria infection in the urinary tract – is valued at nearly $2 billion. With the fast track status, Cubist can expect to own a more »

  • The U.S. Antidepressant Market: Old Fashioned Branding Might Save the Day

    By Amod Saul - July 18, 2013 | Tickers: AZN, AZN, LLY, FRX, GSK, PFE, TRGT

    Over 40% of Americans have used an antidepressant at least once during their lifetime and, at 270 million prescriptions per year, antidepressants are the most consumed class of therapeutics in the US. However, revenue does not match prescription numbers due to fierce generic competition in the class. While retail prices for commonly prescribed branded anti-depressants like Cymbalta can reach over $170 per month, a generic equivalent will cost less than more »

  • Forest Bulks Up Its Cardiovascular Franchise

    By Seth Robey - May 31, 2013 | Tickers: AZN, FRX

    When Forest Laboratories (NYSE: FRX) lost patent protection for Lexapro in March 2012 it lost half of its revenue and an even greater fraction of its profits.  Forest has cushioned the blow with the launch of several new products and nearly $1 billion in cash, and the stock is still trading near 52-week highs despite an annual loss.  In the first quarter, these new products brought in $254 million, or more »

  • Five Super Ideas in the Healthcare Sector

    By Masam Abbas - February 12, 2013 | Tickers: LLY, FRX, MRK, REGN, SGEN

    It will not be wrong if I state that healthcare is the most volatile sector in the world of equities. Drugs come and go. Some are rejected. Others are approved. Hence, the healthcare stocks keep on moving on such news. This sector is the absolute opposite of the transportation sector, which is/has been/will be transporting goods/people from one place to another and hence lacks the sense of more »

  • A Different Pharma Story Altogether

    By Zain Abbas - January 29, 2013 | Tickers: FRX, GSK, JNJ

    Glaxo Smithkline (NYSE: GSK) is expected to report its 4Q12 results on Wednesday 6th February. The sell-side forecasts sales of $11.02 billion (-3% YoY), core EBIT of $3.62 billion (-2% YoY), and basic core EPS of 50 cents (-1% YoY). FX will be a 3% and 4% headwind on sales and EPS. For FY13E, the basic core EPS estimate stands at $1.97 (+9% YoY). The sell-side more »

  • Spring For This Forest

    By tarun bachhawat - January 23, 2013 | Tickers: FRX, GSK, PFE

    Forest Laboratories (NYSE: FRX) released its third quarter earnings on Jan. 15, 2013, and there was nothing pleasing about it. Revenue has fallen over the year, net income has turned into loss, and the company has reduced its future earnings projection. On the face nothing seems to be going right for Forest Laboratories, but let’s take a deeper look in it and what it holds for its investors.

    Dwindling more »

  • Carl Icahn's Top Positions (Part I)

    By Anh HOANG - January 16, 2013 | Tickers: CVI, FRX, HFC, VLO

    Carl Icahn is one of the most famous activist investors in the world. He often purchases a large stake in publicly traded companies and forces them to take corporate actions to significantly increase their market value. When Icahn is building stakes in a particular company, it might indicate an investment opportunity. Let’s have a look at several big positions in Icahn’s current portfolio to see whether or not more »

  • Icahn's Top Activist Holdings

    By Federico Zaldua - January 14, 2013 | Tickers: CHK, FRX, IEP, NAV

    According to Investopedia, Icahn's strategy involves targeting a company he thinks is poorly run and whose stock price is trading below intrinsic value. Icahn buys the stock as it goes materially down. In fact, he thrives when the markets are on a downtrend; when everyone else is selling, he starts buying. He accumulates enough of an ownership position to lobby for a position on the company's board of more »

  • 3 Attractive Stocks in BioPharma To Buy

    By David Gould - November 28, 2012 | Tickers: FRX, MYL, QCOR

    BioPharma stocks have been through quite a tumultuous period over the last few months. From healthcare reform to patent cliffs and corporate takeovers, their betas have been pretty high of late. Research has shown that riskier, high beta stocks tend to outperform their safer counterparts. But is the reward worth bearing the risk? With this question in mind, I review three healthcare stocks below.

    Questcor Pharmaceuticals (NASDAQ: QCOR) Undervalued

    After more »

  • Billionaire Icahn’s Latest Stock Plays

    By Meena Krishnamsetty - November 19, 2012 | Tickers: CVI, FDML, FRX, NAV, NFLX

    Carl Icahn, the infamous corporate raider, made a splash toward the end of the third quarter by deciding to take on Netflix (NASDAQ: NFLX). Other than Netflix, Icahn flew under the radar with a few modest increases in other stocks he owned at the end of 2Q.  Icahn's big move was a 7.5% stake in the natural gas company Chesapeake Energy. Chesapeake is down almost 8% since the more »

  • Is Teva Pharmaceuticals a Good Stock to Buy?

    By Meena Krishnamsetty - October 23, 2012 | Tickers: ACT, AGN, FRX, NVO, TEVA

    Teva Pharmaceuticals' (NYSE: TEVA) business has been doing well so far in 2012. In the first half of the year, revenue was up 22% versus the same period in 2011, including a 19% increase in the second quarter. Operating expenses were up a modest amount, but with a small decrease in share count the company reported $1.96 in earnings per share for the first half of the year; in more »

  • Pharmas Across The Pond

    By AnnaLisa Kraft - October 11, 2012 | Tickers: AMRN, AZN, FRX, GSK, SNY, THRX

    Every time I hear about falling off the patent cliff I can’t help but picture Wiley Coyote in mid-flight realizing he is falling off the cliff with that Acme Company anvil ominously above. Too many Saturday morning cartoons in my past. Some Big Pharma companies aren’t just falling off a patent cliff: they’re more like our coyote friend, flailing wildly to find something to fill up their more »

  • Is This Pharma Stock a Good Investment?

    By Meena Krishnamsetty - September 27, 2012 | Tickers: ABC, ARNA, FRX, QCOR, VVUS

    Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) made our list of terrible twenty stocks earlier this week. Shares of the drug manufacturer have lost more than 60% over the past three months, and are currently a favorite of short sellers – the stock sports a short interest over 30%. These declines come at an interesting time for Questcor, when many investors were buying into the notion of the company’s “multi-functional” drug, Acthar more »

  • Carl Icahn is Increasing His Stake in This Pharma Stock

    By Meena Krishnamsetty - September 11, 2012 | Tickers: AGN, LLY, FRX, PFE, TEVA

    In the past two weeks, activist investor Carl Icahn has purchased nearly 420,000 shares of Forest Laboratories (NYSE: FRX) worth a total of $14.5 million. The transactions, which occurred in seven separate Form 4 filings with the SEC, are part of a larger bullish trend over the past month. Since August 17th, Icahn has increased his position in the pharmaceutical company by 13.9%, and currently holds more »

  • FDA Approval Makes the Price Right for This Pharma Stock

    By Brandy Betz - September 11, 2012 | Tickers: FRX, IRWD, SCMP

    Ironwood Pharmaceuticals (NASDAQ: IRWD) has scored its first FDA approved drug. The official stamp was recently granted to Linzess (linaclotide), a treatment for specific types of irritable bowel syndrome and chronic constipation. The PDUFA wasn’t expected until September 8 but came in early. Investors ran up IRWD share prices to a peak of nearly $16 in the past few months while waiting for an approval, many of whom got more »

  • Is There Money to be Made in These Medical Drug Stocks?

    By Ali Ghorbanzadeh - September 9, 2012 | Tickers: LLY, FRX, OPK, PFE

    In this unstable economic climate, finding ways to outperform the market is much easier said than done. However, one screening tool that has proven to be effective in determining whether a stock is moving higher is insider buying due to one simple reason: they buy stocks, just like us, to make more money. In addition, they arguably have the best view of the company being a part of the day-to-day more »

  • Clinical Trial of New Johnson & Johnson Alzheimer's Drug Fails

    By Muhammad Bazil - July 31, 2012 | Tickers: ELN, FRX, JNJ, PFE

    New Jersey-based healthcare products and consumer packaged goods manufacturer Johnson & Johnson (NYSE: JNJ), announced late on Monday that one group of a Phase II clinical trial of its new drug for the treatment of Alzheimer's disease, bapineuzumab, failed to show that the drug slowed the progression of the disease.  A similar statement was also concurrently issued by Pfizer, Inc. (NYSE: PFE), which acquired an interest in the drug, along more »

  • Merck: Experts In Patent Cliff Management

    By Maxwell Fisher - July 20, 2012 | Tickers: AZN, LLY, FRX, MRK, PFE

    Merck (NYSE: MRK) is engaged in the development and manufacturing of medicines, vaccines, consumer health products, and animal products throughout the world. The vaccines prevent a large number of diseases such as measles, shingles, and mumps, while the prescription products are used in the treatment of cardiovascular and respiratory diseases, oncology, neuroscience and other areas. Consumer health products include Claritin for allergies, Coppertone for skin care, and Dr. Scholl's more »

  • Carl Icahn's Next Turnarounds

    By Mike Thiessen - July 10, 2012 | Tickers: FDML, FRX, GOOG, IEP

    During the first quarter of this year, Carl Icahn and Icahn Associates held over 17 positions in the stock market, valued at almost $10 billion… not a bad little nest egg. But some of his biggest holdings aren’t making the returns Icahn might hope for.

    Of course Icahn’s biggest holding, with a huge 41% of his total portfolio invested, is in Icahn Enterprises, L.P. (NASDAQ: IEP).  It more »

  • Page 1 of 2